Astria Non Currrent Assets Other from 2010 to 2024
| ATXS Stock | USD 8.85 0.02 0.23% |
Non Currrent Assets Other | First Reported 2014-12-31 | Previous Quarter 3.4 M | Current Value 4.1 M | Quarterly Volatility 6.6 M |
Check Astria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astria Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 12.7 M, Other Operating Expenses of 37.7 M or Research Development of 25 M, as well as many indicators such as Price To Sales Ratio of 51.69, Dividend Yield of 0.0 or PTB Ratio of 0.59. Astria financial statements analysis is a perfect complement when working with Astria Therapeutics Valuation or Volatility modules.
Astria | Non Currrent Assets Other |
Latest Astria Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Astria Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Astria Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Astria Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Astria Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 832,403 | |
| Geometric Mean | 279,355 | |
| Coefficient Of Variation | 159.64 | |
| Mean Deviation | 1,018,778 | |
| Median | 135,000 | |
| Standard Deviation | 1,328,837 | |
| Sample Variance | 1.8T | |
| Range | 3.5M | |
| R-Value | 0.70 | |
| Mean Square Error | 974.4B | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 207,490 | |
| Total Sum of Squares | 24.7T |
Astria Non Currrent Assets Other History
About Astria Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Astria Therapeutics income statement, its balance sheet, and the statement of cash flows. Astria Therapeutics investors use historical funamental indicators, such as Astria Therapeutics's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Astria Therapeutics investors may use each financial statement separately, they are all related. The changes in Astria Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Astria Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Astria Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Astria Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 3.4 M | 3.5 M |
Pair Trading with Astria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Astria Stock
| 0.92 | MESO | Mesoblast Fiscal Year End 4th of September 2024 | PairCorr |
| 0.66 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
| 0.61 | JPHLF | Japan Post Holdings | PairCorr |
| 0.58 | JPSTF | JAPAN POST BANK | PairCorr |
The ability to find closely correlated positions to Astria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astria Therapeutics to buy it.
The correlation of Astria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Astria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Astria Stock Analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.